With the belief of customer experience first, the company provides its clients with a full range of differentiated CDMO services from the perspective of business leader. And based on a deep understanding of customers’ actual needs and combined with the company's past experience in all stage biologics development projects, direct-to-target product development, manufacturing and regulatory filings for global biopharmaceutical companies and biotechnology companies was provided by the company with a flexible thinking and operation mode. Through lean and quality management, the company achieves controllable drug supply cost, and improves the accessibility of high-quality biologic products for customers, which creates values for global patients.

Up to April 2022, the Company platform has undertaken 26 customer projects, including 8 in the preclinical research stage, 12 in the early clinical stage (Phase I, Phase II), and 2 in the late clinical stage (Phase III) and 1 in the commercial production stage.

It is estimated that by the end of 2023, the total MFG capacity of the company will exceed 20,000 liters and will continue to provide customers with cost-controlled biologic products that meets international quality standards through strong industrialization capabilities.